Khiron Life Sciences Corp. (KHRN.V)
| Previous Close | 0.0400 |
| Open | 0.0450 |
| Bid | 0.0350 x 0 |
| Ask | 0.0450 x 0 |
| Day's Range | 0.0400 - 0.0450 |
| 52 Week Range | 0.0350 - 0.1650 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 9.296M |
| Beta (5Y Monthly) | 3.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1700 |
| Earnings Date | Nov 28, 2023 - Dec 04, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileKhiron Life Sciences Announces Closing of the Sale of Its European Business
Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron" or the "Company") is pleased to announce that the Company has completed the sale of its European subsidiaries, being Khiron Europe GmbH ("Khiron Europe"), Zerenia Clinics Limited ("Zerenia UK"), PharmaDrug Production GmbH ("Pharmadrug"), Khiron Life Sciences UK Limited ("Khiron UK") and Khiron Life Sciences Spain SL ("Khiron Spain", and collectively with Khiron Europe, Zereni
NewsfileKhiron Life Sciences Announces Update to the Proposed Sale of Its European Business
Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTC Pink: KHRNF) ("Khiron" or the "Company") today announced that the Company and 2518542 Alberta Ltd., a company controlled by Avonlea Drewry Holdings Inc. (the "Purchaser"), have entered into an amended and restated share purchase agreement (the "Restated Purchase Agreement") dated November 15, 2023, providing for the purchase and sale of the Company's European subsidiaries. Under the terms of the
NewsfileKhiron Life Sciences Agrees to $500,000 Secured Deposit
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) ("Khiron" or the "Company") announced today that the Company has agreed to a $500,000 non-interesting bearing refundable deposit from 2518542 Alberta Ltd. ("251"), a company controlled by Avonlea-Drewry Holdings Inc., to be secured by all of Khiron's present and after-acquired property pursuant to a general security agreement and a pledge of Khiron's shares in its subsidiaries, Pharmadrug P
